Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Dental AnesthesiaAnesthesia, LocalAnesthesia, Reversal
Interventions
DRUG

OraVerse

1.8mL dental cartridge delivered in doses of either 1/4, 1/2 or 1 cartridge depending on subject weight

OTHER

Sham injection

No drug administered, simulation of injection used in same manner as drug

Trial Locations (7)

15261

University of Pittsburgh School of Dental Medicine, Pittsburgh

43205

Nationwide Children's Hospital, Columbus

46202

Indiana University School of Dentistry, Indianapolis

84124

Jean Brown Research, Salt Lake City

94143

University of California, San Francisco, San Francisco

98115

Center for Pediatric Dentistry, Seattle

19104-6030

University of Pennsylvania School of Dental, Philadelphia

All Listed Sponsors
lead

Novocol Pharmaceutical of Canada, Inc.

INDUSTRY

NCT01474382 - Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients | Biotech Hunter | Biotech Hunter